

Certificate of Analysis

Human 10-Donor Pooled Cryopreserved Hepatocytes Grade S, Qualified for Suspension Assays

FOR RESEARCH USE ONLY. Not intended for human or animal diagnostic or therapeutic uses. HUMAN CRYOPRESERVED SUSPENSION HEPATOCYTES <u>are not recommended for cultivation</u>. Human primary cells must be treated as potential pathogens. Users need to <u>wear</u> personal protective equipment during work. DO NOT USE DRY ICE DURING WORK, STORAGE, OR TRANSPORTATION.

Catalog number: HEP-S-10 Batch numbers: HEP190027

1. Information about donors

Batch number	Sex	Ethnicity	Age	Alcohol use	Tobacco use	Pathology or Cause of death
number						
HEP723	F	Caucasian	64	No	No	Hepatocellular carcinoma
HEP725	М	Caucasian	18	No	No	Blunt head trauma
HEP730	М	Caucasian	71	No	No	Hemorrhagic stroke
HEP732	F	Caucasian	38	No	No	Right Hemangioma
HEP736	F	Caucasian	71	No	No	Hemorrhagic stroke
HEP737	М	Caucasian	74	No	No	Rectal cancer
HEP743	М	Caucasian	71	No	No	Sigmoid colon cancer
HEP745	F	Caucasian	63	No	No	Cancer colon
HEP747	М	Caucasian	61	No	No	Colon cancer
HEP748	F	Caucasian	86	No	No	Hemorrhagic stroke

Biological materials were collected from certified clinical hospitals. Clinical site provided ethical committee approval and conducted the collection in accordance with the Directive 2004/23/EC of the European Parliament

2. Viral RNA Detection by qPCR

Virus	Specification	Res	ult
Hepatitis B		Positive 🔿	Negative X
Hepatitis C	Negative	Positive 🔿	Negative X
HIV-1 and HIV-2		Positive 🔿	Negative X



3. Product Information

Process	Human hepatocytes were isolated from liver resection and liver autopsy by standard methods. The different batches of human hepatocytes were then pooled and frozen using a proprietary pooling process of TRL-Lonza under a license agreement
Biosafety level	Human-sourced products should be handled at the Biological Safety Level 2 (BSL 2)
Last Control Date	10/09/2024
Packaging	1 ml vial with a minimum of 5×10^6 viable cells
Quality Grade	Grade S qualified as non-plateable cryohepatocytes for suspension and metabolism assay.

4. Cell Quality Control after Thawing

Criteria	Specification	Result	Conclusion	
Post-thaw viability	≥ 75 %	92 %	Yes X	No 🔿
Number of viable cells per vial	≥ 5 x 10 ⁶	6.7 x 10 ⁶	Yes X	No 🔿
Microbial sterility	No microbial growth detectable	Undetectable	Yes X	No 🔿

5. Functional Controls After Thawing

Substrate	Activity	Enzyme	Clint µL/min/mln cells
Phenacetin 1 µM	Phenacetin O-deethylation	CYP1A2	2.9
Coumarin 1 µM	Coumarin 7-hydroxylation	CYP2A6	18.6
Bupropion 1 μM	Bupropion hydroxylation	CYP2B6	1.9
Amodiaquine 1 µM	Amodiaquine N-deethylation	CYP2C8	TBD
Diclofenac 1 µM	Diclofenac 4'-hydroxylation	CYP2C9	23.6
Mephenytoin 5 µM	Mephenytoin hydroxylation	CYP2C19	0.019
Dextromethorphan 1 µM	Dextromethorphan O-demethylation	CYP2D6	14.5
Chlorzoxazone 1 µM	Chlorzoxazone 6-hydroxylation	CYP2E1	0.96
Testosterone 5 μM	Testosterone 6β-hydroxylation	CYP3A4/5	0.232
Nifedipine 1 µM	Nifedipine oxidation	CYP3A4/5	11.5



6. Cell Storage

Delivery	In liquid nitrogen, ≤ -150ºC		
Storage temperature	In vapour of liquid nitrogen, ≤ -150°C		
	up to 5 years		

7. Visa for Batch Release

Name

Signature

Date

Tetiana Papurina

P

16/09/2024